Vaxcyte Inc. (PCVX)$47.30
Market Cap: 4.42 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Vaxcyte Inc. (PCVX).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-6.3x
EV/FCF, N/A FCF yield
Quality
-0.0%
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 7.9x current ratio
Superinvestors
2
Top: Lee Ainslie (0.9%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 8 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 8 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for PCVX.
Grade F
5
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| PCVX Target | Vaxcyte Inc. | $4.4B | -8.4x | -6.3x | -0.0% | N/A | N/A | N/A | N/A | N/A |
| IONS | Ionis Pharmaceuticals Inc. | $5.4B | -31.7x | -21.2x | -16.6% | 5.3% | -33.9% | N/A | N/A | N/A |
| AXSM | Axsome Therapeutics Inc. | $5.7B | -64.1x | -57.1x | -207.5% | N/A | -14.7% | N/A | N/A | N/A |
| LEGN | Legend Biotech Corp. | $6.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| BBIO | BridgeBio Pharma Inc. | $7.3B | -18.3x | -19.5x | N/A | 127.4% | -89.0% | N/A | N/A | N/A |
| HALO | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
| IMVT | Immunovant Inc. | $2.6B | -12.3x | -4.1x | -59.3% | N/A | N/A | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
Financial Charts
No financial data available for PCVX (annual).
2 superinvestors own PCVX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 1,377,738 | $80M | 0.93% | 0.0% |
| Seth Klarman Baupost Group | 800,000 | $46M | 0.91% | 0.0% |